GSP Crop Science IPO

It has built a pretty solid intellectual property base, with 102 granted patents and 108 more applications still under process. Patented products usually face less competition, which gives the company more room to charge better prices and earn stronger margins. What makes that even more meaningful is that these patented products are not just on paper; they actually bring in real business, contributing ₹143.67 crore, or 17.10% of total product sales, in the first half of FY26.

It is not dependent only on India, which gives the business a bit more balance. In FY25, international operations brought in ₹143.93 crore, making up 11.18% of revenue from operations, with the company selling across 37 countries.

It is showing better control over pricing and costs, which simply means it is able to keep a larger share of the money from every sale. Its gross margin rose to 39.57% in FY25 from 27.12% in FY23, while net profit margin improved from 1.46% to 6.26% during the same period.

It reaches farmers through a very wide domestic retail network, which gives it strong ground-level access in the market. With 5,644 active distributors in FY25 and 4,801 by September 2025, the company has been able to push its branded crop protection products deep into farming markets across 20 Indian states.

It runs five manufacturing plants across India, giving it meaningful scale when it comes to production. Its installed annual capacity stands at 43,672 metric tonnes for formulations, meaning ready-to-use products, and 15,120 metric tonnes for technical chemicals, which are the core active ingredients, helping it serve both domestic and export demand efficiently.

It has also built a broad and legally approved product portfolio, which is a big advantage in a regulated business like agrochemicals. By September 2025, it had secured 524 product registrations in India and 236 export registrations, allowing it to sell its crop protection products across 37 countries.

It depends quite a lot on Chinese suppliers for raw materials, and that creates a real risk for the business. In the first half of FY26, imports from China made up 42.08% of total purchases, or ₹228.35 crore, which means any disruption in supply, pricing, or trade flow could directly affect operations.

It also appears to be dealing with fairly high product returns from distributors. In the first half of FY26, sales returns came in at ₹84.61 crore, equal to 8.26% of gross revenue, which may suggest overstocking in the channel or demand at the retail level being weaker than expected.

The company is not fully using some of its manufacturing capacity, which can hurt efficiency and raise costs. For example, in the first half of FY26, the formulation plant at its Odhav unit operated at only 9.92% capacity, while the Samba facility was running at a relatively low 25.02%.

A big share of its domestic revenue comes from only a handful of regions, which adds concentration risk. In the first half of FY26, five Indian states contributed 57.37% of total revenue, with Gujarat alone contributing 27.27% or ₹230.23 crore.

It does not have long-term supply agreements with customers, which means demand can shift more suddenly. Its top 10 customers contributed 22.87% of total revenue, or ₹193.10 crore, in the first half of FY26, so losing even a few key buyers could have a noticeable impact.

A large part of its sales still comes from older generic products, which means off-patent products that are widely available in the market. In the first half of FY26, these products contributed 82.90%, or ₹696.7 crore, of sales, and insecticides alone made up nearly 59% of product revenue, so the overall portfolio is not very diversified.